Michel Detheux - Nov 22, 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Executive Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol
ITOS
Transactions as of
Nov 22, 2021
Transactions value $
-$320,686
Form type
4
Date filed
11/24/2021, 06:59 PM
Previous filing
Nov 3, 2021
Next filing
Dec 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Options Exercise $202K +16.3K +21.28% $12.45 92.7K Nov 22, 2021 Direct F1
transaction ITOS Common Stock Sale -$523K -14.5K -15.64% $36.08 78.2K Nov 23, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (right to buy) Options Exercise $0 -16.3K -100% $0.00* 0 Nov 22, 2021 Common Stock 16.3K $12.45 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.48 to $36.48, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The option is fully vested.